Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer

British Journal of Surgery

Volumn 83, Issue 8, 1996, Pages 1037-1046

  Reid, S E ^a,b   Murthy, M S ^a   Kaufman, M ^a   Scanlon, E F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EVANSTON HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTROGEN; GROWTH FACTOR; PROGESTERONE; SEX HORMONE; STEROID HORMONE;

ADULT; AGED; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HORMONE RELEASE; HUMAN; HUMAN TISSUE; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW;

EID: 0029743633     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830805     Document Type: Review

References (126)

1. Hughes LE, Mansel RE, Wehster DJT. Benign Disorders and Diseases of the Breast. London: Bailliere Tindall, 1989.
2. Furnival CM. Function of the normal breast: physiology and endocrine control. In: Forbes JF, ed. Breast Disease. Edinhurgh: Churchill Livingstone. Clinical Surgery International 1986; 10: 1-19.
3. Russo J, Russo I. Hormonally induced differentiation: a novel approach to breast cancer prevention. J Cell Biochem Suppl 1995; 22: 58-64.
4. Henson DE, Tarone RE. On the possible role of involution in the natural history of breast cancer. Cancer 1993; 71(6 Suppl): 2154-6.
5. Hutson SW, Cowen PN, Bird CC. Morphometric studies of age related changes in normal human breast and their significance for evolution of mammary cancer. J Clin Pathol 1985; 38: 281-7.
6. Anastassiades OT, Spiliades C, Tsakraklides E, Gogas J. Amount and distribution of solid and fatty tissues in the female breast and their relationship to carcinoma. Path Res Pract 1983; 176: 200-15.
7. Bartow SA, Black WC, Waeckerlin RW, Mettler FA. Fibrocystic disease, a continuing enigma. In: Sommers SC, Rosen PP, eds. Pathology Annual 2. Vol. 17. New York: Appleton-Century-Crofts, 1982: 93-111.
8. Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981; 104: 23-34.
9. Potten CS, Watson RJ, Williams GT et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163-70.
10. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
11. Anderson TJ. Mitotic activity in the breast. Journal of Obstetrics and Gynaecology 1984: 4: S114-18.
12. Going JJ, Anderson TJ, Battersby S, Maclntyre CCA. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193-204.
13. Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989; 20: 1139-44.
14. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48-65.
15. Vorherr H. The Breast: Morphology, Physiology and Lactation. New York: Academic Press, 1974.
16. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
17. Kyprianou M, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991; 51: 162-6.
18. Wang TTY, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-9.
19. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histoputhological characteristics and prognosis. Eur J Cancer 1994; 30A: 2068-73.
20. Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397-400.
21. Lippman ME, Dickson RB. Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 1989; 45: 383-440.
22. Sporn MB, Roberts AB. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 1986; 78: 329-32.
23. Dickson RB. Lippman ME. Autocrine and paracrine growth factors in the normal and the neoplastic breast. In: Harris JA, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia, Pennsylvania: Lippincott-Raven, 1996: 272-83.
24. Dickson RB. Biochemical control of breast development. In: Harris JA, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia. Pennsylvania: Lippincott-Raven, 1996: 15-25.
25. Cullen KJ, Lippman ME. Stromal-epithelial interactions in breast cancer. Cancer Treat Res 1992; 61: 413-31.
26. Haslam SZ. Mammary fibroblast influence on normal mouse mammary epithelial cell responses to estrogen in vitro. Cancer Res 1986; 46: 310-16.
27. Coltrera MD, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor β-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995; 55: 2703-8.
28. Kong F, Anscher MS, Murase T, Abbott B, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-62,
29. Flaumenhaft R, Rifkin DB. Extracellular matrix regulation of growth factor and protease activity. Curr Opin Cell Biol 1991; 3: 817-23.
30. Basset P, Wolf C, Rouyer N, Bellocq J, Rio MC, Chambon P. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 1994; 74(3 Suppl): 1045-9.
31. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994; 74(3 Suppl): 1030-44.
32. DeCossc JD, Gossens C, Kuzma JF, Unsworth BR. Embryonic inductive tissues that cause histologic differentiation of murinc mammary carcinoma in vitro. J Natl Cancer Inst 1975; 54: 913-22.
33. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
34. Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metah Clin North Am 1987; 16: 995-1011.
35. Rudman D. Feller AG, Nagraj HS et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
36. Nicolas V, Prewett A, Bettica P et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 1994; 78: 1011-16.
37. Pfeilschifter J, Diel I, Pilz U, Brunotte K, Naumann A, Ziegler R. Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J Bone Miner Res 1993; 8: 707-17.
38. Brucker M, Siddiqui A, Farrell CL, Mustoe TA. Differential expression of PDGF receptor alpha and beta in an aging model of wound repair. Presented at the Owen H Wangensteen Surgical Forun, American College of Surgeons Meeting, 1995.
39. Ruan W, Newman CB, Kleinherg DL. Intact and aminoterminally shortened forms of insulin-like growth factor-1 induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992; 89: 10872-6.
40. Pollak M. Effects of adjuvant tamoxifen therapy on growth hormone and insulin-like growth factor 1 (IGF-I) physiology. In: Salmon SE, ed. Adjuvant Therapy of Cancer VII. Philadelphia, Pennsylvania: JB Lippincott, 1993: 43-54.
41. Thomas DB. Do hormones cause breast cancer? Cancer 1984; 53(3 Suppl): 595-604.
42. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer lnst 1972; 48: 605-13.
43. Spicer DV, Ursin G, Parisky YR et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994: 86: 431-6.
44. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-21.
45. Henson DE, Tarone RE. Involution and the etiology of breast cancer. Cancer 1994; 74(1 Suppl): 424-9.
46. Adami HO, Adams G, Boyle P el al. Breast-cancer etiology. Report of a working party for the Nordic Cancer Union. Int J Cancer Suppl 1990; 5: 22-39.
47. Rookus MA, van Leeuwen FE. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 1994; 344: 844-51.
48. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989; i: 973-82.
49. Williams G, Anderson E, Howell A et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991; 48: 206-10.
50. Thomas DB. Oral contraceptives and breast cancer. J Natl Cancer Inst 1993; 85: 359-64.
51. Henderson BE, Bernstein L. Endogenous and exogenous hormonal factors. In: Harris JA, Lippman ME, Morrow M. Hellman S. eds. Diseases of the Breast. Philadelphia. Pennsylvania: Lippincott-Raven, 1996: 185-200.
52. La Vecchia C, Negri E, Franceschi S et al. Oral contraceptives and breast cancer: a cooperative Italian study. Int J Cancer 1995; 60: 163-7.
53. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987; 56: 653-60.
54. Stadel BV, Schlessclman JJ, Murray PA. Oral contraceptives and breast cancer. Lancet 1989; i: 1257-8 (Letter).
55. Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 1989; 81: 1000-4.
56. Chilvers CED, Smith SJ, UK National Case-Control Study Group. The effect of patterns of oral contraceptive use on breast cancer risk in young women. Br J Cancer 1994; 69: 922-3.
57. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331: 5-9.
58. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47.
59. Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987; 9: 146-74.
60. Byrne C, Schaircr C, Wolfe J et al. Mammographic features and breast cancer risk: effects with time, age. and menopause status. J Natl Cancer Inst 1995; 87: 1622-9.
61. Brisson J, Morrison AS, Khalid N. Mammographic parenchymal features and breast cancer in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988; 80: 1534-40.
62. Whitehead J, Carlile T, Kopecky KJ et al. Wolfe mammographic parenchymal patterns. A study of the masking hypothesis of Egan and Mosteller. Cancer 1985; 56: 1280-6.
63. Bergkvist L, Tabar L, Bergstrom R, Adami HO. Epidemiologic determinants of the mammographic parenchymal pattern. A population based study within a mammographic screening program. Am J Epidemiol 1987; 126: 1075-81.
64. Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br J Cancer 1995; 71: 647-50.
65. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993; 15: 196-208.
66. Boyd NF, Byng JW, Jong RA et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670-5.
67. Dickson RB, Gottardis MM, Merlino GT. Molecular insights with breast cancer from transgenic mouse models. Bioessays 1991; 13: 591-6.
68. Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992; 16: 67-72.
69. Stomper PC, Van Voorhis BJ, Ravniker VA, Meyer JE. Mammographic changes associated with postmenopausal hormonal replacement therapy: a longitudinal study. Radiology 1990; 174: 487-90
70. Spicer DV, Ursin G, Parisky YR et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86: 431-6.
71. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl Med 1995; 332: 1589-93.
72. La Vecchia CL, Negri E, Franceschi S et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995; 72: 244-8.
73. Stanford JL, Weiss NS. Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-42.
74. Kaufman Z, Garstin WIH, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radial 1991; 43: 389-92.
75. Berkowitz JE, Gatewood OMB, Goldblum LE. Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990; 174: 199-201.
76. Laya MB, Gallagher JC, Schreiman JS, Larson EB. Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995; 196: 433-7.
77. Cyrlak D, Wong CH. Mammographic changes in postmenopausal women undergoing hormonal replacement therapy. AJR Am J Roentgenol 1993: 161: 1177-83.
78. Kvale G, Heuch I. Menstrual factors and breast cancer risk. Cancer 1988; 62: 1625-31.
79. Cooper AP. Practice and Principles of Surgery. In: Hrushesky WJM. Breast cancer and the menstrual cycle. J Surg Oncol 1993; 53: 1-3.
80. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-7.
81. Huggins C. Endocrine-induced regression of cancers. Science 1967; 156: 1050-4.
82. Pritchard KI. Current status of adjuvant endocrine therapy for resectable breast cancer. Semin Oncol 1987; 14: 23-33.
83. Rutqvist LE. The significance of hormone receptors to predict the endocrine responsiveness of human breast cancer. Acta Oncol 1990; 29: 371-7.
84. Cowan K, Lippman M. Steroid receptors in breast cancer. Arch Intern Med 1982; 142: 363-6.
85. Ethier SP. Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 1995; 87: 964-73.
86. Stewart AJ, Wcstey BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992; 66: 640-8.
87. Reid SE, Murthy MS, Kaufman M, Scanlon ES. The role of cytokines and growth factors in promoting the local recurrence of breast cancer. Rr J Surg 1996; 83: 313-20.
88. Hrushesky WJM. Breast cancer and the menstrual cycle. J Surg Oncol 1993; 53: 1-3 (Editorial).
89. McGuire WL, Hilsenbeck S, Clark GM. Optimal mastectomy timing. J Natl Cancer Inst 1992; 84: 346-8.
90. Fentiman IS, Gregory WM. Peri-operative hormones and prognosis in breast cancer, Eur J Cancer 1994; 30A: 1892-4.
91. Veronesi U, Luini A, Mariani L et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 343: 1545-7.
92. Badwe RA, Gregory WM, Chaudary MA et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991; 337: 1261-4.
93. Senic RT, Rosen PP, Rhodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 1991; 115: 337-42.
94. Oliver DJ, Ingram DM. Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 1995; 31A: 325-8.
95. Bergkvist L, Adami HO. Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221-8.
96. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400-4.
97. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11-17.
98. Galle R, Vilcoq JR, Zafrani B, Vielh P, Fourquct A. Local control and survival of breast cancer treated by limited surgery followed by irradiation, Int J Radiat Oncol Biol phys 1986; 12: 873-8.
99. Haffty BG, Wilmarth L, Wilson L, Fischer D, Beinfield M, McKhann C. Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patient. Cancer 1994; 73: 2543-8.
100. Kurtz JM. Factors influencing the risk of local recurrence in the breast. Eur J Cancer 1992; 28: 660-6.
101. Fowble BL, Schultz DJ, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994; 30: 23-33.
102. Borger J, Kemperman H, Hart A, Peterse J, van Dongen J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol 1994; 12: 653-60.
103. Locker AJ, Ellis IO, Morgan ADL, Elston CW, Mitchell A, Blamey RW. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surs 1989; 76: 890-4.
104. Donegan WL, Perez-Masa CM, Watson FR. A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 1966; 122: 529-40.
105. Matthews RH, McNeesc MD, Montague ED, Oswald MJ. Prognostic implications of age in breast cancer patients treated with tumorectomy and irradiation or with mastectomy. Int J Radiat Oncol Biol Phys 1988; 14: 659-63.
106. Veronesi U, Luini A, Del Vecchio M et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993; 328: 1587-91.
107. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995; 87: 19-27.
108. Harris JR, Recht A. Conservative surgery and radiotherapy. In: Harris JR, Hellman S, Henderson IC, Kinne DW, ed's. Breast Diseases. 2nd ed. Philadelphia, Pennsylvania: JB Lippincott, 1991: 388-419.
109. Nixon AJ, Neuberg D, Hayes DF et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J clin Oncol 1994; 12: 888-94.
110. Kurtz JM. Factors which predict breast relapse. Recent Results Cancer Res 1993; 127: 137-50.
111. Meyer JS. Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. Monogr Natl Cancer Inst 1986; 1: 25-8.
112. Silvestrini R, Daidone MG, Di Fronzo G. Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 1979; 44: 665-70.
113. Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. Monogr Natl Cancer Inst 1994: 16: 23-4.
114. Olsson H, Ranstam J, Baldetorp B et al. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer 1991; 67: 1285-90.
115. de la Rochefordiere A, Asselain B, Campana F et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-43.
116. Silvestrini R, Daidone MG, Luisi A et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995; 13: 697-704.
117. Meyer JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994; 74: 2287-99.
118. Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol 1992; 8: 161-6.
119. Dutt PL, Page DL. Multicentricity of in situ and invasive carcinoma. In: Bland KI, Copeland EM III, eds. The Breast: Comprehensive Management of Benign and Malignant Diseases. Philadelphia, Pennsylvania: WB Saunders, 1991: 299-308.
120. Morimoto T, Okazaki K, Komaki K et al. Cancerous residue in breast-conserving surgery. J Surg Oncol 1993; 52: 71-6.
121. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J, Uppsala-Orebro Breast Cancer Study Group. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. J Natl Cancer Inst 1994; 86: 717-22.
122. Whelan T, Clark R, Roberts R, Levine M, Foster G, Investigators of the Ontario Clinical Oncology Group. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial, Int J Radiat Oncol Biol Phys 1994; 30: 11-16.
123. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? Monogr Natl Cancer Inst 1994; 16: 35-42.
124. Schinzinger AS. Uber carcinoma mammae. Beilage zum Centralblatt fur Chirurgie 1889; 16: 55.
125. Schinzinger AS. Das karzinom der mamma. Muenchener Medizinische Wochenschrift 1905; 52: 1724-5.
126. Horsley JS. Bilateral oophorectomy with radical operation for cancer of the breast. Surgery 1944; 15: 590-601.